Energy and Commerce Committee Ranking Member Frank Pallone, Jr. (D-New Jersey) has formally initiated a sweeping oversight investigation into the entities responsible for adjudicating payment disputes under the No Surprises Act, signaling a major escalation in congressional efforts to curb rising healthcare costs. On Thursday, Pallone dispatched detailed oversight letters to six prominent independent dispute resolution (IDR) entities: C2C Innovative Solutions, Commence, Dane Street, EdiPhy Advisors, National Medical Reviews, and ProPeer Resources. The inquiry seeks to determine whether these third-party arbitrators are operating in accordance with federal law and whether their decision-making processes are inadvertently fueling a surge in insurance premiums and out-of-pocket expenses for American consumers.
The No Surprises Act, which went into effect in January 2022, was designed as a landmark piece of consumer protection legislation. Its primary objective was to shield patients from "balance billing"—the practice where out-of-network providers bill patients for the difference between their charges and the amount covered by insurance. This frequently occurred in emergency situations or when patients received care from out-of-network specialists at in-network facilities. While the law has successfully protected millions of families from catastrophic medical debt, the mechanism created to resolve the underlying financial disputes between insurers and providers—the IDR process—has become a flashpoint for controversy and administrative strain.
The Mechanics of the Independent Dispute Resolution Process
Under the framework of the No Surprises Act, when a provider and an insurer cannot agree on the payment for an out-of-network service, they are required to enter a 30-day period of open negotiation. If a resolution is not reached within this window, either party may initiate the IDR process. This process utilizes a "baseball-style" arbitration, where each party submits a final payment offer to a certified IDR entity. A neutral arbitrator then selects one of the two offers, with no option for a middle-ground compromise.
The arbitrator’s decision is intended to be guided by several factors, including the Qualifying Payment Amount (QPA)—which is the insurer’s median in-network rate for a similar service in the same geographic area—as well as other relevant information such as the provider’s level of training or the complexity of the specific case. However, the law explicitly prohibits arbitrators from considering the provider’s billed charges or the rates paid by government programs like Medicare and Medicaid.
A System Overwhelmed: The Data Behind the Backlog
The primary impetus for Representative Pallone’s investigation is the staggering discrepancy between the projected use of the IDR process and its actual implementation. When the No Surprises Act was being drafted, the Congressional Budget Office (CBO) and the Centers for Medicare & Medicaid Services (CMS) estimated that approximately 17,000 disputes would be filed annually. This estimate was based on the assumption that the threat of arbitration would encourage providers and insurers to reach voluntary agreements.
The reality has been dramatically different. In 2025, the number of disputes filed reached a staggering 2.5 million. This 14,000% increase over original projections has created a massive administrative backlog and raised questions about the sustainability of the current system. According to the announcement from Pallone’s office, a significant portion of these cases appears to be driven by a small, concentrated group of providers, many of whom are backed by private equity firms. Critics argue that these entities are using the IDR process as a primary business strategy to secure payments far exceeding standard market rates, rather than using it as a last resort for genuine disputes.
Financial Implications and the Role of Private Equity
The financial stakes of the IDR process are immense. Data cited by the Energy and Commerce Committee indicates that IDR entities awarded approximately $15 billion in payments to providers in 2025 alone. Perhaps more concerning to policymakers is the win rate for providers, which exceeded 85% in recent determinations. Furthermore, these awards were often significantly higher than local in-network rates—sometimes by as much as six times.
"For too long, patients were caught in the middle of billing disputes between providers and health plans," Pallone stated in his letters to the six firms. "While the law has protected millions of families from surprise medical bills, I am concerned that the independent dispute resolution process is not functioning as Congress intended and is resulting in increased out-of-pocket costs and higher premiums for consumers."
The involvement of private equity-backed healthcare groups is a central theme of the investigation. These firms often manage large practices in specialties such as emergency medicine, anesthesiology, and radiology—areas where patients have little choice over their provider. By aggressively pursuing arbitration, these firms can potentially inflate the "market rate" for services, which in turn forces insurers to raise premiums to cover the increased payouts. This dynamic creates a "hidden" cost for consumers: while they no longer receive a surprise bill in the mail, they pay for it through higher monthly insurance costs.
Chronology of the No Surprises Act and Legal Challenges
The path to the current investigation has been marked by legislative triumph followed by intense legal and operational friction.
- December 2020: The No Surprises Act is signed into law as part of the Consolidated Appropriations Act, 2021, receiving broad bipartisan support.
- January 2022: The law officially takes effect. Almost immediately, the Department of Health and Human Services (HHS) faces a series of lawsuits from provider groups, most notably the Texas Medical Association (TMA).
- 2022–2023: Federal courts in Texas issue several rulings that strike down portions of the administration’s implementation rules. Specifically, the courts ruled that the government had placed too much emphasis on the QPA, arguing that arbitrators should have more discretion to consider other factors.
- 2024: The IDR portal is frequently paused and reopened as the government attempts to update its processes in response to court orders. The volume of disputes continues to skyrocket, leading to the 2.5 million figure cited by Pallone.
- September 2024: Representative Pallone issues oversight letters to the six IDR entities, demanding transparency on their internal metrics and selection processes.
Specific Demands of the Oversight Investigation
Representative Pallone has set a deadline of September 24 for the six companies to provide comprehensive data regarding their operations. The letters request specific information aimed at identifying potential biases or systemic flaws in the arbitration process. The requested data points include:
- Selection Criteria: Detailed explanations of how the entities determine which payment offer to select and how much weight is given to the QPA versus other factors.
- Conflict of Interest Disclosures: Information regarding any relationships between the IDR entities and the private equity firms or healthcare providers involved in the disputes.
- Efficiency and Backlog Data: Metrics on the time taken to resolve disputes and the reasons for the continued growth of the case backlog.
- Financial Transparency: A breakdown of the fees collected by the IDR entities and how those fees impact the overall cost of the resolution process.
Pallone expressed frustration with the current lack of transparency, noting that committee staff had previously requested information from these companies without receiving substantive responses. "I am concerned about your lack of transparency with Congress," he wrote, emphasizing that corporate entities may be using "aggressive tactics" to undermine the spirit of the law.
Broader Impact and Policy Implications
The outcome of this investigation could have profound implications for the future of healthcare reimbursement in the United States. If the Energy and Commerce Committee finds that IDR entities are indeed favoring high-cost offers without sufficient justification, it may lead to new legislative proposals to tighten the arbitration process.
One potential policy shift could involve a "benchmark" system, where payments are capped at a certain percentage of Medicare rates or a more strictly defined QPA, reducing the need for arbitration altogether. Another possibility is the implementation of stricter penalties for "frivolous" arbitration filings to discourage the high volume of cases currently clogging the system.
From a consumer perspective, the investigation highlights a critical tension in healthcare policy: the trade-off between protecting individuals from specific financial shocks and managing the aggregate costs of the healthcare system. While the No Surprises Act has been a success in its primary mission—protecting the patient at the point of service—the "back-end" battle between multi-billion dollar insurance companies and private equity-backed provider groups remains a significant driver of inflation.
As the September 24 deadline approaches, the healthcare industry will be watching closely. The responses from C2C Innovative Solutions, Commence, Dane Street, EdiPhy Advisors, National Medical Reviews, and ProPeer Resources will likely shape the next phase of the No Surprises Act’s evolution, determining whether the law can fulfill its promise of lowering costs or if it will continue to be a theater for high-stakes financial litigation.
